Multiple sclerosis

Journal of Clinical Investigation

Volumn 113, Issue 6, 2004, Pages 788-794

  Hafler, David A ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; DNA; GLATIRAMER; MITOXANTRONE; RNA; SYNTHETIC PEPTIDE;

CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DRUG MECHANISM; GERM LINE; HAPLOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HYPOTHESIS; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

EID: 2142662186     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI21357     Document Type: Review

References (96)

1. Charcot, J. 1868. Comptes rendus des séances et mémoires lus à la société de Biologie.
2. Charcot, J. 1868. Histologie de la sclérose en plaque. Gazette des Hôpitaux. 41:554-566.
3. Charcot, J. 1877. Lectures on the diseases of the nervous system. The New Sydenham Society. London, United Kingdom. 157-222.
4. Kabat, E.A., Glusman, M., and Knaub, V. 1948. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am. J. Med. 4:653-662.
5. Kabat, E.A., Freedman, D.A., Murray, J.P., and Knaub, V. 1950. A study of the crystalline albumin, gamma globulin and the total protein in the cerebrospinal fluid of one hundred cases of multiple sclerosis and other diseases. Am. J. Med. Sci. 219:55-64.
6. Mackay, R.P., and Myrianthopoulos, N.C. 1966. Multiple sclerosis in twins and their relatives. Arch. Neurol. 15:449-462.
7. Williams, A., et al. 1980, Multiple sclerosis in twins. Neurology. 30:1139-1147.
8. Ebers, G.C., et al. 1986. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 315:1638-1642.
9. Heltberg, A., and Holm, N. 1982. Concordance in twins and recurrence in sibships in MS. Lancet. 1:1068.
10. Kinnunen, E., Koskenvuo, M., Kaprio, J., and Aho, K. 1987. Multiple sclerosis in a nationwide series of twins. Neurology. 37:1627-1629.
11. Utz, U., et al. 1993. Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature. 364:243-247.
12. Mumford, C., et al. 1992. The UK study of MS in twins. J. Neurol. 239:62.
13. French Research Group on Multiple Sclerosis. 1992. MS in 54 twinships: concordance rare is independent of zygosity. Ann. Neurol. 32:724-727.
14. Rivers, T.M., Sprunt, D.H., and Berry, G.P. 1933. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58:39-53.
15. Hafler, D.A. 1999. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J. Clin. Invest. 104:527-529.
16. Ben-Nun, A., Wekerle, H., and Cohen, I.R. 1981. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11:195-199.
17. Goverman, J., et al. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell. 72:551-560.
18. Trapp, B.D., et al. 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-285.
19. Wucherpfennig, K.W., et al. 1992. T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J. Exp. Med. 175:993-1002.
20. Traugott, U., Reinherz, E.L., and Raine, C.S. 1983. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science. 219:308-310.
21. Hauser, S.L., et al. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19:578-587.
22. Wucherpfennig, K.W., et al. 1992. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc. Natl. Acad. Sci. U. S. A. 89:4588-4592.
23. Prineas, J. W., and Wright, R.G. 1978. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 38:409-421.
24. Prineas, J. 1975. Pathology of the early lesion in multiple sclerosis. Hum. Pathol. 6:531-554.
25. Lucchinetti, C.F., Bruck, W., Rodriguez, M., and Lassmann, H. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:259-274.
26. Pohl-Koppe, A. Burchett, S.K., Thiele, E.A., and Hafler, D.A. 1998. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J. Neuroimmunol. 91:19-27.
27. Khoury, S.J., Hancock, W.W., and Weiner, H.L. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355-1364.
28. Weinshenker, B.G. 1994. Natural history of multiple sclerosis. Ann. Neurol. 36(Suppl):S6-S11.
29. Confavreux, C., Vukusic, S., Moreau, T., and Adeleine, P. 2000. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343:1430-1438.
30. Khouty, S.J., et al. 1994. Longitudinal MRI imaging in multiple sclerosis: correlation between disability and lesion burden. Neurology. 44:2120-2124.
31. Filippi, M., et al. 1995. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 45:255-260.
32. Hohol, M.J., et al. 1999. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult. Scler. 5:403-409.
33. McDonald, W.I., et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50:121-127.
34. Achiron, A., and Barak, Y. 2000. Multiple sclerosis - from probable to definite diagnosis: a 7-year prospective study. Arch Neurol. 57:974-979.
35. Griffin, D.E. 1990. Monophasic autoimmune inflammatory diseases of the CNS and PNS. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 68:91-104.
36. O'Connor, K.C., et al. 2003. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J. Neuroimmunol. 136:140-148.
37. Genain, C.P., Cannella, B., Hauser, S.L., and Raine, C.S. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:170-175.
38. Bourdette, D. Antel, J., McFarland, H., and Montgomery, E. 1999. Monitoring relapsing remitting MS patients. J. Neuroimmunol. 98:16-21.
39. Barkhof, F., et al. 1992. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am. J. Roentgenol. 159:1041-1047.
40. Yednock, T.A., et al. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 356:63-66.
41. Miller, D.H., et al. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15-23.
42. Lehmann, P.V., Forsthuber, T., Miller, A., and Sercarz, E.E. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:155-157.
43. Miller, S.D., et al. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 3:739-745.
44. Windhagen, A., et al 1995. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1985-1996.
45. Ota, K., et al. 1990. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 346:183-187.
46. Pette, M., et al. 1990. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurobiology. 40:1770-1776.
47. Martin, R., et al. 1990, Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145:540-548.
48. Ausubel, L.J., Kwan, C.K., Sette, A., Kuchroo, V., and Hafler, D.A. 1996 Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones. Proc. Natl. Acad. Sci. U. S. A. 93:15317-15322.
49. Hemmer, B., et al. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185:1651-1659.
50. Wucherpfennig, K.W., and Stominger, J.L. 1995 Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80:695-705.
51. Scholz, C., Patton, K.T., Anderson, D.E., Freeman, G.J., and Hafler, D.A. 1998. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 160:1532-1538.
52. Lovett-Racke, A.E., et al. 1998. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101:725-730.
53. Evavold, B.D., and Allen, P.M. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 252:1308-1310.
54. Sloan-Lancaster, J., Shaw, A.S., Rothbard, J.B., and Allen, P.M. 1994. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell. 79:913-922.
55. Nicholson, L.B., Murtaza, A., Hafler, B.P., Sette, A., and Kuchroo, V.K. 1997. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. U. S. A. 94:9279-9284.
56. Nicholson, L.B., Greer, J.M., Sobel, R.A., Lees, M.B., and Kuchroo, V.K. 1995 An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity. 3:397-405.
57. Brocke, S., et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:343-346.
58. Windhagen, A., et al. 1995. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:373-380.
59. Ausubel, L.J., Krieger, J.I., and Hafler, D.A. 1997. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J. Immunol. 159:2502-2512.
60. Ausubel, L.J., Bieganowska, K.D., and Hafler, D.A. 1999. Cross reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein. Cell. Immunol. 193:99-107.
61. Bielekova, B., et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167-1175.
62. Kappos, L., et al. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6:1176-1182.
63. Bornstein, M.B., et al. 1987. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 41:533-539.
64. Fridkis-Hareli, M., and Strominger, J.L. 1998. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160:4386-4397.
65. Johnson, K.P., et al. 1998. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 80:701-708.
66. Filippi, M., et al. 2001. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology. 57:731-733.
67. Duda, P.W., Krieger, J.I., Schmied, M.C., Balentine, C., and Hafler, D.A. 2000. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol. 165:7300-7307.
68. Duda, P.W., Schmied, M.C., Cook, S.L., Krieger, J.I., and Hafler, D.A. 2000. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105:967-976.
69. Qin, Y., Zhang, D.Q., Prat, A., Pouly, S., and Antel, J. 2000. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol. 108:201-206.
70. Dabbert, D., et al. 2000. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci. Lett. 289:205-208.
71. Stuve, O., et al. 1996. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:853-863.
72. Dyment, D.A., and Ebers, G.C. 2002. An array of sunshine in multiple sclerosis. N. Engl. J. Med. 347:1445-1447.
73. Robertson, N.P., et al. 1997. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet. 349:1587-1590.
74. Dean, G., McLoughlin, H., Brady, R., Adelstein, A.M., and Tallett-Williams, J. 1976. Multiple sclerosis among immigrants in greater London. Br. Med. J. 1:861-864.
75. Kurtzke, J.F., Gudmundsson, K.R., and Bergmann, S. 1982. MS in Iceland. 1. Evidence of a post-war epidemic. Neurology. 32:143-150.
76. Carton, H., et al. 1997. Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. J. Neurol. Neurosurg. Psychiatr. 62:329-333.
77. Robertson, N.P., Clayton, D., Fraser, M., Deans, J., and Compston, D.A. 1996. Clinical concordance in sibling pairs with multiple sclerosis. Neurology. 47:347-352.
78. Sadovnick, A., Baird, P., and Ward, R. 1988. Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet. 39:533-541.
79. Risch, N. 1990. Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am. J. Hum. Genet. 46:229-241.
80. Sawcer, S., and Goodfellow, P.N. 1998. Inheritance of susceptibility to multiple sclerosis. Curr. Opin. Immunol. 10:697-703.
81. Allen, M., et al. 1994. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum. Immunol. 39:41-48.
82. Coraddu, F., et al. 1998. HLA associations with multiple sclerosis in the Canary Islands. J. Neuroimmunol. 87:130-135.
83. Haegert, D.G., et al. 1993. HLA-DQA1 and -DQB1 associations with multiple sclerosis in Sardinia and French Canada: evidence for immunogenetically distinct patient groups. Neurology. 43:548-552.
84. Hauser, S.L., et al. 1989. Extended major histocompatibility complex haplotypes in patients with multiple sclerosis. Neurology. 39:275-277.
85. Kellar-Wood, H.F., et al. 1995. Multiple sclerosis and the HLA-D region: linkage and association studies. J. Neuroimmunol. 58:183-190.
86. Olerup, O., Hillert, J., and Fredrikson, S. 1990. The HLA-D region-associated MS-susceptibility genes may be located telomeric to the HLA-DP subregion. Tissue Antigens. 36:37-39.
87. Haines, J.L., et al. 1996. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. 13:469-471.
88. Sawcer, S., et al. 1996. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13:464-468.
89. Ebers, G.C., et al. 1996. A full genome search in multiple sclerosis. Nat. Genet. 13:472-476.
90. Kruglyak, L. 1999. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat. Genet. 22:139-144.
91. Daly, M.J., Rioux, J.D., Schaffner, S.F., Hudson, T.J., and Lander, E.S. 2001. High-resolution haplotype structure in the human genome. Nat. Genet. 29:229-232.
92. Gabriel, S.B., et al. 2002. The structure of haplotype blocks in the human genome. Science. 296:2225-2229.
93. Reich, D.E., et al. 2001. Linkage disequilibrium in the human genome. Nature. 411:199-204.
94. Johnson, G.C., et al. 2001. Haplotype tagging for the identification of common disease genes. Nat. Genet. 29:233-237.
95. Rioux, J.D., et al. 2001. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 29:223-228.
96. Viglietta, V., Baecher-Allan, C., and Hafler, D. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. Exp. Med. In press.